Trial Filter
BETAAn intelligent search tool for clinical trials
Official Title
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
Phase
Phase 1
Sponsor
Eli Lilly and Company
Enrollment
360
Timeline
Feb 2026 → Dec 2029
About This Study
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Eligibility Criteria
Inclusion Criteria
- 1Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:
- 2Diffuse large B-cell lymphoma - not otherwise specified
- 3High-grade B-cell lymphoma
- 4Follicular large B-cell lymphoma
- 5Follicular lymphoma
- 6Other non-Hodgkin lymphoma
- 7Has measurable disease
- 8Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy
Exclusion Criteria
- 1Has an active second cancer
- 2Has known or suspected history of central nervous system involvement
- 3Has known Cytomegalovirus infection. Participants with negative status are eligible
- 4Has known hepatitis B or C infection or HIV
- 5Has significant heart disease
Locations
19 sites participating in this study
Emory University Hospital
Atlanta, Georgia 30322
City of Hope
Duarte, California 91010
University of California, Los Angeles (UCLA) - Medical Center
Los Angeles, California 90059
Data sourced from ClinicalTrials.govView on ClinicalTrials.gov →